Breast and thyroid cancer: A multicenter study with Accrual to Clinical Trials Network

Merry Peckham; Horace J Spencer; Shorabuddin Syed; William B Armstrong; Donald Gregory Farwell; Thomas J Gal; David Goldenberg; Marika D Russell; Roberto N Solis; Deanne King; Brendan C Stack

doi:10.1002/jso.26825

Breast and thyroid cancer: A multicenter study with Accrual to Clinical Trials Network

J Surg Oncol. 2022 Jun;125(8):1211-1217. doi: 10.1002/jso.26825. Epub 2022 Feb 23.

Authors

Affiliations

¹ University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
² Department of Otolaryngology - Head and Neck Surgery, University of California, Irvine, California, USA.
³ Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
⁴ Department of Otolaryngology - Head and Neck Surgery, University of Kentucky, Lexington, Kentucky, USA.
⁵ Department of Otolaryngology - Head and Neck Surgery, The Pennsylvania State University, Hershey, Pennsylvania, USA.
⁶ Department of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, California, USA.
⁷ Department of Otolaryngology - Head and Neck Surgery, University of California, Davis, Davis, California, USA.
⁸ Department of Otolaryngology - Head and Neck Surgery, Southern Illinois University School of Medicine, Springfield, Illinois, USA.

Abstract

Objective: To investigate a possible link between breast and thyroid cancer.

Methods: A multicenter retrospective review of patients in the electronic medical records of six Accrual to Clinical Trial (ACT) institutions with both breast cancer and thyroid carcinoma. Each center queried its data using a predefined data dictionary. Information on thyroid and breast cancer included dates of diagnosis, histology, and patient demographics.

Results: A random-effects model was used. There were 4.24 million women's records screened, 44 605 with breast cancer and 11 846 with thyroid cancer. The relative risks observed at each institution ranged from 0.49 to 13.47. The combined risk ratio (RR) estimate was 1.77 (95% confidence interval: 0.50-5.18).

Conclusion: There was no association between the risk of developing thyroid cancer and being a breast cancer survivor compared to no history of breast cancer, but the range of relative risks among the participating institutions was wide. Our findings warrant further study of more institutions with larger sample size. Additionally, further analysis of the significance of regional RR differences may be enlightening.

Keywords: breast cancer; epidemiology; thyroid cancer.

Publication types

Multicenter Study

MeSH terms

Breast Neoplasms* / drug therapy
Data Collection
Female
Humans
Risk
Thyroid Neoplasms* / epidemiology
Thyroid Neoplasms* / therapy

Abstract

Publication types

MeSH terms

Grants and funding